Roivant Sciences Jumps 24% on Positive Phase 2 Mosliciguat Data
Updated
Updated · CNBC · Sep 8
Roivant Sciences Jumps 24% on Positive Phase 2 Mosliciguat Data
2 articles · Updated · CNBC · Sep 8
Summary
Roivant Sciences surged 24% premarket after saying Pulmovant’s Phase 2 trial met a key efficacy mark in pulmonary hypertension with interstitial lung disease.
Phase 2 results showed mosliciguat delivered a clinically meaningful, statistically significant placebo-adjusted reduction in pulmonary vascular resistance, the company said.
The gain stood out among sharp healthcare moves before the bell: Novartis fell 12% after a Phase 3 setback, while Boston Scientific slipped more than 2% after warning a cyberattack could hit 2026 sales and profit targets.
The rally signals investor appetite for mid-stage drug data in hard-to-treat lung disease, especially when trial results show both statistical significance and clinical relevance.